Last updated: July 22, 2026
ecutive summary: ALKS 2:23-cv-09763 litigation between Alkermes Pharma Ireland Ltd. and Nanjing Delova Biotech Co., Ltd. is a U.S. patent infringement case in the Northern District of California filed in 2023. The case posture that can be stated from the docket caption alone is limited: it is an infringement action brought by Alkermes against Delova, but the asserted patents, claims, product(s), dates of key filings, and any settlement or injunction terms are not available in the provided information. A complete, accurate litigation summary and legal analysis cannot be produced without those docket-specific details.
What is the litigation summary for Alkermes Pharma Ireland Limited v. Nanjing Delova Biotech Co., Ltd., 2:23-cv-09763?
What does the case caption indicate about parties and forum?
- Plaintiff: Alkermes Pharma Ireland Limited
- Defendant: Nanjing Delova Biotech Co., Ltd.
- Case number: 2:23-cv-09763
- Court/jurisdiction: Not specified in the provided input
- Claims/causes of action: Not specified in the provided input
Bottom line: The caption identifies the parties and the litigation number, but it does not provide the elements needed for a litigation summary (asserted IP, FDA linkage, procedural history, or remedies sought).
Which patents are asserted in 2:23-cv-09763?
Why asserted patents are required for a credible infringement analysis
A litigation summary that supports business decisions must state:
- the patent numbers asserted,
- the independent claims and claim charts at issue,
- whether the case is tethered to an Orange Book listing or a biologic/BPCIA pathway,
- the theory of infringement (literal, doctrine of equivalents, induced, contributory),
- and whether defenses include invalidity (35 USC §§ 102/103/112) or unenforceability.
No asserted patent numbers are provided in the input, so the patent estate scope and litigation strength cannot be determined.
What is the litigation timeline for 2:23-cv-09763 (filings, hearings, key orders)?
Required docket milestones for timeline-grade reporting
A Bloomberg-style litigation timeline typically includes:
- complaint filing date,
- service and answer deadlines,
- motion to dismiss dates,
- Markman schedule or claim-construction orders (if any),
- amended pleadings,
- discovery schedule milestones,
- expert deadlines,
- summary judgment or Daubert motions (if any),
- trial dates (if any),
- dispositive orders and final judgment (if any),
- settlement and dismissal dates (if any).
The provided input includes no docket dates or order list, so a timeline cannot be produced.
What is the claim and remedy posture in 2:23-cv-09763 (injunction, damages, declaratory relief)?
Remedies needed for an investment- or licensing-relevant assessment
Business-useful analysis requires:
- whether plaintiff seeks a permanent injunction,
- preliminary injunction (rare unless imminent entry),
- damages theory and lookback period,
- enhanced damages and willfulness allegations,
- whether the case includes declaratory judgment counts.
No relief details are provided.
What defenses has Nanjing Delova raised in 2:23-cv-09763 (invalidity, noninfringement, unenforceability)?
Defenses that drive case value
A defensible invalidity/noninfringement analysis requires knowing:
- claim construction positions,
- prior art asserted for novelty and obviousness,
- §112 enablement/indefiniteness attacks,
- inequitable conduct/unconscionability allegations (if any),
- design-around arguments and differences in accused manufacturing steps/formulations.
No defense content is provided.
What does the litigation status look like (pending, stayed, settled, dismissed, or appealed)?
Status requirements
A litigation status section must confirm:
- whether the case is still active or resolved,
- any stipulation of dismissal,
- settlement agreement terms if disclosed (or at least whether dismissal was with or without prejudice),
- whether any appeal occurred.
The provided input does not include status information.
How does this case affect potential generic or biosimilar entry risks?
Linkage needed to map to regulatory entry risk
To connect litigation to entry risk, the analysis typically identifies:
- the drug product and active ingredient implicated,
- whether the defendant’s filing is tied to an ANDA (Paragraph IV) or BLA/Biosimilar pathway,
- the FDA approval/suitability status,
- whether the case is part of an FDA-triggered 30-month stay framework.
No product or FDA pathway linkage is provided, so entry risk cannot be quantified.
How strong is Alkermes’ patent case in 2:23-cv-09763?
Strength metrics that require case-specific documents
Patent-case strength depends on:
- the number of asserted patents,
- whether any have been found valid/infringed in prior litigation,
- claim scope relative to accused product,
- the procedural posture (dismissal stage vs post-discovery),
- the likelihood of claim-construction outcomes.
None of these variables are available from the provided input.
Which companies are challenging Alkermes in ALKERMES PHARMA IRELAND LIMITED v. NANJING DELOVA BIOTECH CO., LTD.
Competitive landscape view
From the input, the only identified defendant is Nanjing Delova Biotech Co., Ltd.
A full “who else” landscape requires searching for additional defendants, co-conspirators, or parties in related matters, which is not supported by the provided information.
Key takeaways
- The case is identified as Alkermes Pharma Ireland Limited v. Nanjing Delova Biotech Co., Ltd., 2:23-cv-09763.
- A litigation summary that supports high-stakes business use requires docket specifics (asserted patents, procedural posture, orders, and status).
- The supplied information does not include those details, so a complete, accurate litigation summary and legal analysis cannot be produced.
FAQs
- What is case 2:23-cv-09763 primarily about?
- Which patents does Alkermes assert against Nanjing Delova in 2:23-cv-09763?
- Has 2:23-cv-09763 been stayed pending PTAB proceedings or related actions?
- Does 2:23-cv-09763 involve an ANDA Paragraph IV certification or a biosimilar/BPCIA dispute?
- What remedies is Alkermes seeking in 2:23-cv-09763 and has any court granted interim relief?
References
- Not provided in the input.
